C/CPublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Basal cell carcinoma compared to the general population.
C/TPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Basal cell carcinoma.
T/TPublished research associates this genotype with typical/baseline likelihood of Basal cell carcinoma — no copies of the reported risk allele.
Nature communications · 2016 · PMID 27539887 · open access
Questions about rs1050529
What is rs1050529?
rs1050529 is a single position in the genome, in or near the HLA-B gene. Published research associates it with basal cell carcinoma. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
What conditions is rs1050529 linked to?
On MyGeneLog this position is linked to Basal Cell Carcinoma. The research behind each link, and its sources, are set out on that condition page.
Does rs1050529 affect how medicines work?
HLA-B carries pharmacogenomic findings for Abacavir, Allopurinol, Carbamazepine and oxcarbazepine. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Does having rs1050529 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs1050529 come from?
GWAS Catalog, Nat Commun 2016, PMID:27539887. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.